U.S. Familial Adenomatous Polyposis Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

U.S. Familial Adenomatous Polyposis Treatment Market Segmentation, By Treatment Type (Pharmacological Therapy, Surgical Treatment, and Genetic Counseling & Monitoring), Stage of Disease (Advanced Colonic Polyposis, Polyp Development Stage, Post-Surgical Management, Early Stage, and Extra-Colonic Manifestations), Age Group (Adult, Middle-Aged, Pediatric, and Geriatric), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers (ASCS), Academic & Research Institutes, and Genetic Counseling Centers), Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, and Online Pharmacies) - Industry Trends and Forecast to 2032

Familial Adenomatous Polyposis Treatment Market Size

• The U.S. familial adenomatous polyposis treatment market size was valued at USD 659.11 million by 2032 from USD 494.18 million in 2024, growing with a substantial CAGR of 3.7% during the forecast period
• The market growth is primarily driven by rising awareness and genetic counseling
• Additionally, the improved capacity to identify FAP patients earlier and more accurately expands the addressable market for surveillance and potential therapeutic interventions, stimulating demand for new management strategies

Familial Adenomatous Polyposis Treatment Market Analysis

• The U.S. market is experiencing steady growth driven by increased awareness of early genetic screening and the availability of advanced diagnostic technologies for Familial Adenomatous Polyposis (FAP)
• The presence of well-established healthcare infrastructure, favorable reimbursement policies, and a strong pipeline of clinical research are supporting the adoption of targeted therapies and surgical interventions across the country
• The pharmacological therapy segment is expected to dominate the market with 40.55% by 2025, driven by the growing emphasis on non-invasive disease management, expanded clinical use of NSAIDs and targeted agents, and increased accessibility to oral medications. The availability of multiple drug classes such as COX-2 inhibitors, DFMO, EGFR inhibitors, and novel small molecule therapies, along with diverse routes of administration including oral,
• The surgical treatment segment is growing with the CAGR of 4.8% due to the growing emphasis on non-invasive disease management, expanded clinical use of NSAIDs and targeted agents and intravenous, subcutaneous, and topical further supports the segment's growth

Report Scope and Familial Adenomatous Polyposis Treatment Market Segmentation

Familial Adenomatous Polyposis Treatment Market Trends

“Shift Toward Non-Surgical, Targeted Therapies”

• The U.S. is witnessing a strong trend toward non-surgical and targeted therapeutic options for the treatment of Familial Adenomatous Polyposis (FAP), driven by advancements in precision medicine and unmet clinical needs
• According to preliminary results presented at Digestive Disease Week 2025, investigational drugs like REC‑4881 and eRapa have demonstrated significant reductions in polyp burden, indicating their potential to delay or even eliminate the need for colectomy in certain FAP patients
• These emerging therapies offer targeted mechanisms—such as MEK1/2 inhibition and mTOR modulation—which aim to reduce polyp growth while preserving normal intestinal tissue, improving both clinical outcomes and patient quality of life
• As surgical colectomy remains invasive with lifelong consequences, there is a growing preference for oral therapies and immunomodulators that provide less disruptive, long-term management solutions—particularly for younger or asymptomatic mutation carriers
• The growing regulatory support from the FDA through Orphan Drug and Fast Track designations is further catalyzing R&D investment and accelerating clinical trials in the U.S., reinforcing the market’s pivot toward minimally invasive pharmacological alternatives to traditional surgical care

Familial Adenomatous Polyposis Treatment Market Dynamics

Driver

“Rising Awareness and Genetic Counseling”

• The Familial Adenomatous Polyposis (FAP) treatment market is currently experiencing significant acceleration, primarily driven by a robust and continuously expanding awareness of FAP among both the general public and specialized healthcare professionals
• This acceleration is significantly influenced by the rising awareness of FAP, which is intricately linked to the increasing accessibility and sophisticated utilization of genetic counseling services nationwide
• For instance, In May 2025, according to the American Society of Clinical Oncology (ASCO), famitinib demonstrated sustained clinical efficacy and meaningful survival benefits in patients with FAP-associated aggressive desmoid tumors after a median follow-up of 32 months. The report also indicated that, given the unique characteristics of these tumors, careful monitoring for intestinal perforation and the risk of second primary tumors was crucial during treatment
• Moreover, rising awareness and genetic counseling are primary and accelerating drivers of the FAP treatment market growth in the forecast period

Restraint/Challenge

“Limited Patient Population”

• As a designated rare genetic disorder, FAP affects a comparatively tiny fraction of the overall populace, with incidence rates estimated at a mere 1 in 5,000 to 10,000 live births
• This inherently small patient pool presents considerable challenges in terms of market size, rendering it demonstrably less appealing for substantial, large-scale pharmaceutical investments when compared to the vast commercial potential of treatments for more prevalent conditions
• Furthermore, this scarcity of affected individuals creates profound difficulties in recruiting a statistically sufficient number of patients for robust and adequately powered clinical trials, which are indispensable for demonstrating the safety and efficacy of new therapies
• The limited patient population of FAP, a rare genetic disorder, acts as a significant constraint on the U.S. treatment market, making it less attractive for large-scale pharmaceutical investment and complicating clinical trial recruitment

Familial Adenomatous Polyposis Treatment Market Scope

The market is segmented into five notable segments based on treatment type, stage of disease, age group, end user, and distribution channel.

• By Treatment Type

On the basis of treatment type, the U.S. familial adenomatous polyposis treatment market is segmented into pharmacological therapy, surgical treatment, and genetic counseling & monitoring. In 2025, pharmacological therapy segment is expected to dominate the market with a 40.55% owing to the growing emphasis on non-invasive disease management, expanded clinical use of NSAIDs and targeted agents, and increased accessibility to oral medications.

The surgical treatment segment is anticipated to witness the fastest growth rate of 4.8% from 2025 to 2032, due to the continued reliance on colectomy and related surgical interventions as the standard of care for moderate to advanced Familial Adenomatous Polyposis (FAP) cases.

• By Stage of Disease

On the basis of stage of disease, the U.S. familial adenomatous polyposis treatment market is segmented into advanced colonic polyposis, polyp development stage, post-surgical management, early stage, and extra-colonic manifestations. The advanced colonic polyposis segment held the largest market revenue share in 2025, driven by the increased need for immediate surgical or intensive pharmacological intervention in patients with a high polyp burden.

The advanced colonic polyposis segment is expected to witness the fastest CAGR from 2025 to 2032, driven by the increasing incidence of late-diagnosed FAP cases and the higher clinical urgency associated with advanced-stage polyp burden.

• By Age Group

On the basis of age group, the U.S. familial adenomatous polyposis treatment market is segmented into adult, middle-aged, pediatric, and geriatric. The adult segment held the largest market revenue share in 2025, driven by the high diagnostic prevalence of FAP in individuals between late adolescence and early adulthood. Many patients begin to develop polyps in their teenage years, with diagnosis and treatment often initiated in early adulthood.

The adult segment is expected to witness the fastest CAGR from 2025 to 2032, due to the rising diagnosis rates of Familial Adenomatous Polyposis (FAP) in individuals aged 19–55, coupled with increased participation in genetic screening programs and routine colonoscopic surveillance.

• By End User

On the basis of end user, the U.S. familial adenomatous polyposis treatment market is segmented into hospitals, specialty clinics, Ambulatory Surgical Centers (ASCs), academic & research institutes, and genetic counseling centers. The hospitals segment accounted for the largest market revenue share in 2025, driven by the integrated care services they provide, from genetic diagnostics and surgical treatment to long-term disease management.

The hospitals segment is expected to witness the fastest CAGR from 2025 to 2032, driven by the increasing number of FAP-related surgical procedures, enhanced access to advanced diagnostic tools, and the central role of hospitals in administering complex treatments such as colectomy and endoscopic polypectomy.

• By Distribution Channel

On the basis of distribution channel, the U.S. familial adenomatous polyposis treatment market is segmented into hospital pharmacies, specialty pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment accounted for the largest market revenue share in 2025, driven by the critical role hospitals play in dispensing medications during inpatient care and post-surgical treatment. Hospital pharmacies provide immediate access to pharmacological therapies, including NSAIDs, targeted therapies, and chemopreventive agents, which are essential for managing complex FAP cases.

The hospital pharmacies segment is expected to witness the fastest CAGR from 2025 to 2032, due to the growing administration of specialized and investigational FAP therapies that require controlled dispensing and close clinical supervision.

Familial Adenomatous Polyposis Treatment Market Share

The familial adenomatous polyposis treatment industry is primarily led by well-established companies, including:

• Pfizer Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Merck & Co., Inc. (U.S.)
• Medtronic (Ireland)
• Olympus Corporation (Japan)
• Ambry Genetics (U.S.)
• Invitae Corporation (U.S.)
• Boston Scientific Corporation (U.S.)
• Color Health, Inc. (U.S.)
• Emtora Biosciences (U.S.)
• Ethicon (Johnson and Johnson) (U.S.)
• Panbela Therapeutics, Inc. (U.S.)
• Recursion (U.S.)
• SLA Pharma (UK) Limited (U.K.)
• Takeda Pharmaceutical Company Limited (Japan)
• Myriad Genetics, Inc. (U.S.)

Latest Developments in Familial Adenomatous Polyposis Treatment Market

• In April 2025, Merck & Co., Inc. broke ground on a new USD 1 billion Biologics Center of Excellence in Wilmington, Delaware. This state-of-the-art facility is aimed at expanding Merck’s biologics manufacturing capabilities, supporting the development and production of innovative medicines, especially in oncology and immunology
• In June 2025, F. Hoffmann-La Roche Ltd announced a strategic collaboration with Broad Clinical Labs to accelerate the adoption of SBX sequencing technology, an advanced platform designed to enhance genomic profiling and precision diagnostics. This partnership aims to integrate Broad’s cutting-edge sequencing innovation with Roche’s global diagnostic expertise, potentially transforming cancer and rare disease diagnostics through faster, more accurate genetic insights
• In September 2024, Medtronic expanded its AiBLE spine surgery ecosystem by introducing advanced surgical technologies and deepening its strategic partnership with Siemens Healthineers. This development integrates AI-driven imaging and real-time navigation to enhance precision in spine procedures
• In June 2025, Pfizer entered into an exclusive global (ex-China) licensing agreement with 3SBio for SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, showing early promise in cancers like non-small cell lung cancer and metastatic colorectal cancer. This deal includes rights for development, manufacturing, and commercialization outside China, with a USD 1.25 billion upfront payment and potential milestones up to USD 4.8 billion
• In February 2025, Myriad Genetics announced a strategic partnership with PathomIQ to integrate artificial intelligence (AI)-powered technology into its oncology portfolio. This collaboration aims to enhance Myriad's tumor profiling and molecular diagnostic capabilities by leveraging PathomIQ’s AI platform to deliver more precise, data-driven insights for cancer care. The impact of this development is expected to significantly improve diagnostic accuracy and personalized treatment planning for oncology patients

SKU-74388